利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.009 秒)

    Process for preparation of improved mutant strain of Bordetella bronchiseptica useful for live attenuated vaccine for protection of B. bronchiseptica infection and live attenuated AR vaccine produced therefrom
    2.
    发明授权
    Process for preparation of improved mutant strain of Bordetella bronchiseptica useful for live attenuated vaccine for protection of B. bronchiseptica infection and live attenuated AR vaccine produced therefrom 失效
    制备可用于减毒支气管炎支原体感染活疫苗疫苗和由其生产的减毒减毒AR疫苗的博德特氏菌支链球菌改良突变株的方法

    公开(公告)号：US4770875A

    公开(公告)日：1988-09-13

    申请号：US119075

    申请日：1987-11-10

    申请人： Katsumi Kume ,  Toyotsugu Nakai ,  Hiroshi Nishizawa ,  Takashi Yoshikawa ,  Hirofumi Danbara

    发明人： Katsumi Kume ,  Toyotsugu Nakai ,  Hiroshi Nishizawa ,  Takashi Yoshikawa ,  Hirofumi Danbara

    IPC分类号： C12N15/09 ,  A61K39/10 ,  C12N1/20 ,  C12N15/00 ,  C12R1/01 ,  C12N1/00

    CPC分类号： A61K39/099 ,  Y10S424/825 ,  Y10S424/83

    摘要： A process for the preparation of a mutant strain of B. bronchiseptica having chromosomal genetic markers carrying at least temperature-sensitive (grown at 42.degree. C.), nalidixic acid-resistant and heat-labile dermonecrotic toxin producing ability negative markers, suitable for the preparation of live attenuated AR vaccine, which comprises subjecting a strain of B. bronchiseptica to an induced mutation, isolating a mutant having the genetic markers of being at least temperature-sensitive (grown at 42.degree. C.), nalidixic acid-resistant and heat-labile dermonecrotic toxin negative, culturing the isolated strain of B. bronchiseptica on a Bordet-gengou agar plate containing nalidixic acid at 42.degree. C., thereafter picking up an organism morphologically resembling a phase-I organism, repeating the procedures of culturing and picking up, and converting the organisms to a heat-labile dermonecrotic toxin-producing ability negative phase-I organism having a complete capsular antigen.

    摘要翻译： 一种制备支气管炎支原体突变菌株的方法，该菌株具有至少具有温度敏感性（42℃生长），萘啶酸耐受性和热不稳定性皮肤坏死毒素生成能力阴性标记的染色体遗传标记，适用于 活的减毒AR疫苗的制备，其包括使支气管炎支原体菌株进行诱导突变，分离具有至少温度敏感性（在42℃生长）的遗传标记的突变体，耐萘啶酸和热 可溶性皮肤坏死毒素阴性，在含有萘啶酸的Bordet-gengou琼脂平板上培养支气管炎支原体的分离菌株，然后取出形态上类似于I期生物体的生物，重复培养和采摘的程序 并将生物体转化为具有完全荚膜抗原的热不稳定的皮肤坏死毒素生产能力的负相I生物体。

    Pasteurella multocida vaccine
    4.
    发明授权
    Pasteurella multocida vaccine 失效
    巴氏杆菌多杀巴斯德疫苗

    公开(公告)号：US4999191A

    公开(公告)日：1991-03-12

    申请号：US190533

    申请日：1988-05-05

    申请人： John R. Glisson ,  Charles L. Hofacre

    发明人： John R. Glisson ,  Charles L. Hofacre

    IPC分类号： A61K39/102

    CPC分类号： A61K39/102 ,  Y10S424/826 ,  Y10S424/83

    摘要： Mutogenesis of the Clemson University (CU) vaccine strain of P. multocida with N-methyl-N-nitro-N-nitrosoguanidine resulted in temperature sensitive (TS) mutants which grew at 37.degree. C. but not 42.degree. C. Two mutants, PM#1 and PM#3, were found to provide turkeys with a level of protection against challenge with a virulent serotype 3 P. multocida strain (P-1059) comparable to the protection provided by the CU strain. Intravenous (IV) inoculation of PM#1, PM#3, and CU was used to determine differences in virulence. PM#1 and PM#3 resulted in lower mortality and lameness than the CU strain. Histopathological evaluation of spleens at 24, 48, and 72 hours post IV inoculation demonstrated that the CU strain induced 2 times more splenic necrosis than either PM#1 or PM#3.

    摘要翻译： 具有N-甲基-N-硝基-N-亚硝基胍的多杀巴氏杆菌克隆斯大学（CU）疫苗株的发生导致温度敏感（TS）突变体，其在37℃而不是42℃生长。两个突变体， 发现PM＃1和PM＃3为具有与CU菌株提供的保护相当的强毒血清型3 P.多球菌菌株（P-1059）提供了一定的防御水平的火鸡。 使用PM＃1，PM＃3和CU的静脉内（IV）接种来确定毒力的差异。 PM＃1和PM＃3导致比CU菌株更低的死亡率和跛行。 IV接种后24,48和72小时脾脏的组织病理学评估表明，CU菌株比PM＃1或PM＃3诱导2倍以上的脾坏死。

    Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype
    5.
    发明授权
    Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype 失效
    具有相同表型的多个突变的遗传减毒细菌疫苗

    公开(公告)号：US4681762A

    公开(公告)日：1987-07-21

    申请号：US580588

    申请日：1984-02-16

    申请人： Max P. Oeschger ,  Anne M. Hooke ,  Joseph A. Bellanti

    发明人： Max P. Oeschger ,  Anne M. Hooke ,  Joseph A. Bellanti

    IPC分类号： A61K39/102 ,  C12N15/00 ,  A61K39/02 ,  C12N1/20

    CPC分类号： C12R1/21 ,  A61K39/102 ,  C12N15/00 ,  A61K2039/522 ,  Y10S424/83

    摘要： The present invention relates to a vaccine composition for the prevention of infectious diseases comprising an immunogenically-effective amount of a genetically attenuated and stable avirulent bacterial strain derived from a virulent bacterial strain by introducing into said virulent strain by genetic transfer and recombination at least two mutations of the same phenotype which renders said virulent strain avirulent, while permitting said avirulent strain to retain immunogenicity, together with an inert pharmacologically acceptable carrier. It also relates to a method for preparing the vaccine.

    摘要翻译： 本发明涉及一种用于预防感染性疾病的疫苗组合物，其包含免疫有效量的来自有毒细菌菌株的遗传减毒和稳定无毒力菌株，通过遗传转移和重组将至少两个突变引入所述毒力菌株 的同一表型，其使所述毒力无毒素，同时允许所述无毒力菌株保持免疫原性，以及惰性药理学上可接受的载体。 它还涉及一种制备疫苗的方法。

    Turkey rhinotracheitis vaccine
    6.
    发明授权
    Turkey rhinotracheitis vaccine 失效
    土耳其鼻气管炎疫苗

    公开(公告)号：US4379140A

    公开(公告)日：1983-04-05

    申请号：US224402

    申请日：1981-01-12

    申请人： Marcus M. Jensen

    发明人： Marcus M. Jensen

    IPC分类号： A61K39/05 ,  A61K39/02 ,  C12N1/20

    CPC分类号： C12R1/05 ,  A61K39/05 ,  A61K2039/552 ,  Y10S424/826 ,  Y10S424/83

    摘要： A live vaccine against Alcaligenes faecalis, for application to turkeys, containing a temperature-sensitive non-virulent genetically stable strain of Alcaligenes faecalis having good immunizing capabilities and the absence of adverse side-effects.

    摘要翻译： 一种针对产碱杆菌的活疫苗，适用于火鸡，其含有具有良好免疫能力和不存在不良副作用的耐温性非致病性遗传稳定的粪产碱杆菌菌株。